(UNH) UnitedHealth - Overview

Sector: Healthcare | Industry: Healthcare Plans | Exchange: NYSE (USA) | Market Cap: 353.486m USD | Total Return: 22.6% in 12m

Health Insurance, Pharmacy Services, Healthcare Analytics, Care Delivery
Total Rating 71
Safety 72
Buy Signal 1.10
Healthcare Plans
Industry Rotation: +15.6
Market Cap: 353B
Avg Turnover: 2.57B
Risk 3d forecast
Volatility39.9%
VaR 5th Pctl5.49%
VaR vs Median-24.7%
Reward TTM
Sharpe Ratio0.61
Rel. Str. IBD78
Rel. Str. Peer Group75
Character TTM
Beta0.054
Beta Downside0.278
Hurst Exponent0.497
Drawdowns 3y
Max DD61.39%
CAGR/Max DD-0.09
CAGR/Mean DD-0.25
EPS (Earnings per Share) EPS (Earnings per Share) of UNH over the last years for every Quarter: "2021-03": 5.31, "2021-06": 4.7, "2021-09": 4.52, "2021-12": 4.48, "2022-03": 5.49, "2022-06": 5.57, "2022-09": 5.79, "2022-12": 5.34, "2023-03": 6.26, "2023-06": 6.14, "2023-09": 6.56, "2023-12": 6.16, "2024-03": 6.91, "2024-06": 6.8, "2024-09": 6.51, "2024-12": 6.81, "2025-03": 6.85, "2025-06": 4.08, "2025-09": 2.92, "2025-12": 2.11, "2026-03": 7.23,
EPS CAGR: -12.30%
EPS Trend: -63.9%
Last SUE: 3.15
Qual. Beats: 1
Revenue Revenue of UNH over the last years for every Quarter: 2021-03: 70196, 2021-06: 71321, 2021-09: 72337, 2021-12: 73743, 2022-03: 80149, 2022-06: 80332, 2022-09: 80894, 2022-12: 82787, 2023-03: 91931, 2023-06: 92903, 2023-09: 92361, 2023-12: 94427, 2024-03: 99796, 2024-06: 98855, 2024-09: 100820, 2024-12: 100807, 2025-03: 109575, 2025-06: 111616, 2025-09: 113161, 2025-12: 113215, 2026-03: 111721,
Rev. CAGR: 9.69%
Rev. Trend: 99.6%
Last SUE: 1.97
Qual. Beats: 1

Warnings

Below Avwap Earnings

Tailwinds

Supp Ema8, Confidence, Garp

Description: UNH UnitedHealth

UnitedHealth Group Incorporated (UNH) is a diversified healthcare enterprise operating through four primary segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The company utilizes a vertically integrated business model that combines insurance underwriting with direct care delivery, pharmacy benefit management, and data analytics. This structure allows the firm to manage the entire patient lifecycle, from clinical treatment to financial reimbursement.

The UnitedHealthcare division manages a broad range of health benefit plans for employers, individuals, and government programs including Medicare and Medicaid. Complementing this, the Optum segments provide specialized pharmacy services, healthcare technology, and outpatient clinical care. As a leader in the Managed Health Care sub-industry, the company benefits from the long-term trend of value-based care, which prioritizes patient outcomes over the volume of services provided.

For a deeper look into the companys valuation metrics, consider exploring the data on ValueRay. Founded in 1974 and headquartered in Minnesota, UnitedHealth Group maintains a significant footprint in both domestic and international healthcare markets.

Headlines to Watch Out For
  • Optum Health value-based care expansion drives long-term segment margin growth
  • Medicare Advantage reimbursement rates and utilization trends impact UnitedHealthcare profitability
  • Federal antitrust investigations and regulatory scrutiny pose risks to vertical integration
  • Optum Rx pharmacy services scale offsets rising medical loss ratios in insurance
  • Government contract wins and Medicaid redeterminations influence total membership revenue growth
Piotroski VR‑10 (Strict) 5.5
Net Income: 12.04b TTM > 0 and > 6% of Revenue
FCF/TA: 0.06 > 0.02 and ΔFCF/TA -1.74 > 1.0
NWC/Revenue: -5.11% < 20% (prev -4.19%; Δ -0.92% < -1%)
CFO/TA 0.07 > 3% & CFO 23.15b > Net Income 12.04b
Net Debt (49.92b) to EBITDA (22.99b): 2.17 < 3
Current Ratio: 0.80 > 1.5 & < 3
Outstanding Shares: last quarter (910.0m) vs 12m ago -0.87% < -2%
Gross Margin: 18.80% > 18% (prev 0.22%; Δ 1.86k% > 0.5%)
Asset Turnover: 144.5% > 50% (prev 132.4%; Δ 12.14% > 0%)
Interest Coverage Ratio: 4.71 > 6 (EBITDA TTM 22.99b / Interest Expense TTM 3.96b)
Altman Z'' 1.47
A: -0.07 (Total Current Assets 91.13b - Total Current Liabilities 114.12b) / Total Assets 312.64b
B: 0.32 (Retained Earnings 99.88b / Total Assets 312.64b)
C: 0.06 (EBIT TTM 18.66b / Avg Total Assets 311.22b)
D: 0.48 (Book Value of Equity 99.88b / Total Liabilities 207.32b)
Altman-Z'' Score: 1.47 = BB
Beneish M -2.90
DSRI: 0.90 (Receivables 26.59b/26.94b, Revenue 449.71b/410.06b)
GMI: 1.17 (GM 18.80% / 21.99%)
AQI: 1.03 (AQ_t 0.67 / AQ_t-1 0.65)
SGI: 1.10 (Revenue 449.71b / 410.06b)
TATA: -0.04 (NI 12.04b - CFO 23.15b) / TA 312.64b)
Beneish M-Score: -2.90 (Cap -4..+1) = A
What is the price of UNH shares? As of May 21, 2026, the stock is trading at USD 383.30 with a total of 7,772,393 shares traded.
Over the past week, the price has changed by -4.45%, over one month by +18.49%, over three months by +33.20% and over the past year by +22.55%.
Is UNH a buy, sell or hold? UnitedHealth has received a consensus analysts rating of 4.15. Therefore, it is recommended to buy UNH.
  • StrongBuy: 14
  • Buy: 6
  • Hold: 5
  • Sell: 1
  • StrongSell: 1
What are the forecasts/targets for the UNH price?
Analysts Target Price 389.2 1.5%
UnitedHealth (UNH) - Fundamental Data Overview as of 21 May 2026
P/E Trailing = 29.3323
P/E Forward = 21.5517
P/S = 0.786
P/B = 3.6542
P/EG = 1.3648
Revenue TTM = 449.71b USD
EBIT TTM = 18.66b USD
EBITDA TTM = 22.99b USD
Long Term Debt = 71.44b USD (from longTermDebt, last quarter)
Short Term Debt = 6.48b USD (from shortTermDebt, last quarter)
Debt = 77.92b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 49.92b USD (from netDebt column, last quarter)
Enterprise Value = 400.17b USD (353.49b + Debt 77.92b - CCE 31.23b)
Interest Coverage Ratio = 4.71 (Ebit TTM 18.66b / Interest Expense TTM 3.96b)
EV/FCF = 20.35x (Enterprise Value 400.17b / FCF TTM 19.67b)
FCF Yield = 4.91% (FCF TTM 19.67b / Enterprise Value 400.17b)
FCF Margin = 4.37% (FCF TTM 19.67b / Revenue TTM 449.71b)
Net Margin = 2.68% (Net Income TTM 12.04b / Revenue TTM 449.71b)
Gross Margin = 18.80% ((Revenue TTM 449.71b - Cost of Revenue TTM 365.16b) / Revenue TTM)
Gross Margin QoQ = 22.74% (prev 16.34%)
Tobins Q-Ratio = 1.28 (Enterprise Value 400.17b / Total Assets 312.64b)
Interest Expense / Debt = 1.23% (Interest Expense 955.0m / Debt 77.92b)
Taxrate = 18.61% (1.48b / 7.96b)
NOPAT = 15.18b (EBIT 18.66b * (1 - 18.61%))
Current Ratio = 0.80 (Total Current Assets 91.13b / Total Current Liabilities 114.12b)
Debt / Equity = 0.75 (Debt 77.92b / totalStockholderEquity, last quarter 103.89b)
Debt / EBITDA = 2.17 (Net Debt 49.92b / EBITDA 22.99b)
Debt / FCF = 2.54 (Net Debt 49.92b / FCF TTM 19.67b)
Total Stockholder Equity = 97.13b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.87% (Net Income 12.04b / Total Assets 312.64b)
RoE = 12.40% (Net Income TTM 12.04b / Total Stockholder Equity 97.13b)
RoCE = 11.07% (EBIT 18.66b / Capital Employed (Equity 97.13b + L.T.Debt 71.44b))
RoIC = 8.70% (NOPAT 15.18b / Invested Capital 174.53b)
WACC = 5.24% (E(353.49b)/V(431.40b) * Re(6.17%) + D(77.92b)/V(431.40b) * Rd(1.23%) * (1-Tc(0.19)))
Discount Rate = 6.17% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares (quarterly) Correlation: -73.61 | Cagr: -1.20%
[DCF] Terminal Value 84.63% ; FCFF base≈21.74b ; Y1≈18.62b ; Y5≈14.48b
[DCF] Fair Price = 428.2 (EV 438.82b - Net Debt 49.92b = Equity 388.91b / Shares 908.1m; r=6.0% [WACC]; 5y FCF grow -17.50% → 3.0% )
EPS Correlation: -63.85 | EPS CAGR: -12.30% | SUE: 3.15 | # QB: 1
Revenue Correlation: 99.64 | Revenue CAGR: 9.69% | SUE: 1.97 | # QB: 1
EPS current Quarter (2026-06-30): EPS=4.85 | Chg30d=+5.78% | Revisions=+50% | Analysts=22
EPS next Quarter (2026-09-30): EPS=3.73 | Chg30d=-4.11% | Revisions=-17% | Analysts=22
EPS current Year (2026-12-31): EPS=18.36 | Chg30d=+2.80% | Revisions=+86% | GrowthEPS=+12.3% | GrowthRev=-0.7%
EPS next Year (2027-12-31): EPS=20.76 | Chg30d=+3.19% | Revisions=+72% | GrowthEPS=+13.1% | GrowthRev=+2.7%
[Analyst] Revisions Ratio: +86%